Oncology Drugs - Czechia | Statista Market Forecast

The revenue in the Oncology Drugs market in Czechia is forecasted to reach US$364.70m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 6.83%, leading to a market volume of US$507.50m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$103.90bn in 2024.
The Czech Republic has seen a significant increase in the adoption of targeted therapy for cancer treatment in recent years.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
Chemotherapeutic agents
Immuno-oncology drugs
Oncology orphan drugs

Radiation therapy
Medical devices

The Oncology Drugs market in Czechia has been steadily growing in recent years, driven by several factors that are unique to the country.

Customer preferences: Czechia has a high incidence of cancer, which has led to an increased demand for oncology drugs. Patients in the country are also increasingly seeking out targeted therapies, which are becoming more widely available. Additionally, there is a growing preference for oral drugs over traditional intravenous treatments, as they offer greater convenience and ease of use.

Trends in the market: One trend in the Oncology Drugs market in Czechia is the increasing use of immunotherapy drugs, which stimulate the body's immune system to fight cancer cells. These drugs have shown promising results in treating various types of cancer and are becoming more widely available in the country. Another trend is the rise of biosimilars, which are cheaper versions of biologic drugs that have already been approved. These drugs are becoming more widely used in Czechia as they offer cost savings compared to the original drugs.

Local special circumstances: One factor that is unique to the Oncology Drugs market in Czechia is the country's healthcare system. The system is publicly funded, which means that patients have access to a range of treatments at no cost. However, the system is also underfunded, which has led to long wait times for certain treatments. This has led some patients to seek out private healthcare options, which can be expensive.

Underlying macroeconomic factors: The Czech economy has been growing steadily in recent years, which has led to increased investment in the healthcare sector. This has led to the development of new treatments and therapies, which are becoming more widely available in the country. Additionally, the country's membership in the European Union has led to greater regulatory harmonization, which has made it easier for companies to bring new drugs to market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.